-DOCSTART- -X- O
BACKGROUND -X- _ O
: -X- _ O
We -X- _ O
undertook -X- _ O
a -X- _ O
2X2 -X- _ O
factorial -X- _ O
, -X- _ O
randomized -X- _ O
controlled -X- _ O
trial -X- _ O
( -X- _ O
RCT -X- _ O
) -X- _ O
to -X- _ O
assess -X- _ O
whether -X- _ O
vitamin -X- _ B-Intervention
D -X- _ I-Intervention
( -X- _ I-Intervention
3 -X- _ I-Intervention
) -X- _ I-Intervention
supplementation -X- _ I-Intervention
( -X- _ I-Intervention
10,000 -X- _ I-Intervention
international -X- _ I-Intervention
units -X- _ I-Intervention
per -X- _ I-Intervention
week -X- _ I-Intervention
) -X- _ I-Intervention
versus -X- _ O
placebo -X- _ B-Comparison
and -X- _ O
gargling -X- _ B-Intervention
versus -X- _ O
no -X- _ B-Comparison
gargling -X- _ I-Comparison
could -X- _ O
prevent -X- _ O
viral -X- _ O
, -X- _ O
clinical -X- _ O
upper -X- _ O
respiratory -X- _ O
tract -X- _ O
infection -X- _ O
( -X- _ O
URTI -X- _ O
) -X- _ O
in -X- _ O
university -X- _ B-Patient
students. -X- _ I-Patient
METHODS -X- _ O
: -X- _ O
We -X- _ O
randomized -X- _ O
600 -X- _ B-Patient
students -X- _ I-Patient
into -X- _ O
4 -X- _ O
treatment -X- _ O
arms -X- _ O
: -X- _ O
1 -X- _ O
) -X- _ O
vitamin -X- _ B-Intervention
D -X- _ I-Intervention
( -X- _ I-Intervention
3 -X- _ I-Intervention
) -X- _ I-Intervention
and -X- _ I-Intervention
gargling -X- _ I-Intervention
, -X- _ I-Intervention
2 -X- _ I-Intervention
) -X- _ I-Intervention
placebo -X- _ I-Intervention
and -X- _ I-Intervention
gargling -X- _ I-Intervention
, -X- _ I-Intervention
3 -X- _ I-Intervention
) -X- _ I-Intervention
vitamin -X- _ I-Intervention
D -X- _ I-Intervention
( -X- _ I-Intervention
3 -X- _ I-Intervention
) -X- _ I-Intervention
and -X- _ I-Intervention
no -X- _ I-Intervention
gargling -X- _ I-Intervention
, -X- _ O
and -X- _ O
4 -X- _ O
) -X- _ O
placebo -X- _ B-Comparison
and -X- _ I-Comparison
no -X- _ I-Comparison
gargling. -X- _ I-Comparison
Students -X- _ O
completed -X- _ O
weekly -X- _ O
electronic -X- _ O
surveys -X- _ O
and -X- _ O
submitted -X- _ O
self-collected -X- _ O
mid- -X- _ O
turbinate -X- _ O
nasal -X- _ O
flocked -X- _ O
swabs -X- _ O
during -X- _ O
September -X- _ O
and -X- _ O
October -X- _ O
in -X- _ O
2010 -X- _ O
or -X- _ O
2011. -X- _ O
Symptomatic -X- _ O
students -X- _ O
also -X- _ O
completed -X- _ O
an -X- _ O
electronic -X- _ O
symptom -X- _ O
diary. -X- _ O
The -X- _ O
primary -X- _ O
and -X- _ O
secondary -X- _ O
outcomes -X- _ O
were -X- _ O
the -X- _ O
occurrence -X- _ O
of -X- _ O
symptomatic -X- _ O
clinical -X- _ O
URTI -X- _ O
and -X- _ O
laboratory -X- _ O
confirmed -X- _ O
URTI -X- _ O
respectively. -X- _ O
RESULTS -X- _ O
: -X- _ O
Of -X- _ B-Outcome
600 -X- _ I-Outcome
participants -X- _ I-Outcome
, -X- _ I-Outcome
471 -X- _ I-Outcome
( -X- _ I-Outcome
78.5 -X- _ I-Outcome
% -X- _ I-Outcome
) -X- _ I-Outcome
completed -X- _ I-Outcome
all -X- _ I-Outcome
surveys -X- _ I-Outcome
while -X- _ I-Outcome
43 -X- _ I-Outcome
( -X- _ I-Outcome
7.2 -X- _ I-Outcome
% -X- _ I-Outcome
) -X- _ I-Outcome
completed -X- _ I-Outcome
none -X- _ I-Outcome
; -X- _ I-Outcome
150 -X- _ I-Outcome
( -X- _ I-Outcome
25.0 -X- _ I-Outcome
% -X- _ I-Outcome
) -X- _ I-Outcome
reported -X- _ I-Outcome
clinical -X- _ I-Outcome
URTI. -X- _ I-Outcome
Seventy -X- _ I-Outcome
participants -X- _ I-Outcome
( -X- _ I-Outcome
23.3 -X- _ I-Outcome
% -X- _ I-Outcome
) -X- _ I-Outcome
randomized -X- _ I-Outcome
to -X- _ I-Outcome
vitamin -X- _ I-Outcome
D -X- _ I-Outcome
( -X- _ I-Outcome
3 -X- _ I-Outcome
) -X- _ I-Outcome
reported -X- _ I-Outcome
clinical -X- _ I-Outcome
URTI -X- _ I-Outcome
compared -X- _ I-Outcome
to -X- _ I-Outcome
80 -X- _ I-Outcome
( -X- _ I-Outcome
26.7 -X- _ I-Outcome
% -X- _ I-Outcome
) -X- _ I-Outcome
randomized -X- _ I-Outcome
to -X- _ I-Outcome
placebo -X- _ I-Outcome
( -X- _ I-Outcome
RR:0.79 -X- _ I-Outcome
, -X- _ I-Outcome
CI -X- _ I-Outcome
( -X- _ I-Outcome
95 -X- _ I-Outcome
) -X- _ I-Outcome
:0.61-1.03 -X- _ I-Outcome
, -X- _ I-Outcome
p -X- _ I-Outcome
= -X- _ I-Outcome
0.09 -X- _ I-Outcome
) -X- _ I-Outcome
. -X- _ I-Outcome
Eighty-five -X- _ I-Outcome
participants -X- _ I-Outcome
( -X- _ I-Outcome
28.3 -X- _ I-Outcome
% -X- _ I-Outcome
) -X- _ I-Outcome
randomized -X- _ I-Outcome
to -X- _ I-Outcome
gargling -X- _ I-Outcome
reported -X- _ I-Outcome
clinical -X- _ I-Outcome
URTI -X- _ I-Outcome
compared -X- _ I-Outcome
to -X- _ I-Outcome
65 -X- _ I-Outcome
participants -X- _ I-Outcome
( -X- _ I-Outcome
21.7 -X- _ I-Outcome
% -X- _ I-Outcome
) -X- _ I-Outcome
randomized -X- _ I-Outcome
to -X- _ I-Outcome
the -X- _ I-Outcome
no -X- _ I-Outcome
gargling -X- _ I-Outcome
arm -X- _ I-Outcome
( -X- _ I-Outcome
RR:1.3 -X- _ I-Outcome
, -X- _ I-Outcome
CI -X- _ I-Outcome
( -X- _ I-Outcome
95 -X- _ I-Outcome
) -X- _ I-Outcome
:0.92-1.57 -X- _ I-Outcome
, -X- _ I-Outcome
p -X- _ I-Outcome
= -X- _ I-Outcome
0.19 -X- _ I-Outcome
) -X- _ I-Outcome
. -X- _ I-Outcome
Laboratory -X- _ I-Outcome
testing -X- _ I-Outcome
identified -X- _ I-Outcome
70 -X- _ I-Outcome
infections -X- _ I-Outcome
( -X- _ I-Outcome
46.7 -X- _ I-Outcome
per -X- _ I-Outcome
100 -X- _ I-Outcome
URTIs -X- _ I-Outcome
) -X- _ I-Outcome
. -X- _ I-Outcome
Vitamin -X- _ I-Outcome
D -X- _ I-Outcome
( -X- _ I-Outcome
3 -X- _ I-Outcome
) -X- _ I-Outcome
treatment -X- _ I-Outcome
was -X- _ I-Outcome
associated -X- _ I-Outcome
with -X- _ I-Outcome
a -X- _ I-Outcome
significantly -X- _ I-Outcome
lower -X- _ I-Outcome
risk -X- _ I-Outcome
for -X- _ I-Outcome
laboratory -X- _ I-Outcome
confirmed -X- _ I-Outcome
URTI -X- _ I-Outcome
( -X- _ I-Outcome
RR -X- _ I-Outcome
: -X- _ I-Outcome
0.54 -X- _ I-Outcome
, -X- _ I-Outcome
CI -X- _ I-Outcome
( -X- _ I-Outcome
95 -X- _ I-Outcome
) -X- _ I-Outcome
:0.34-0.84 -X- _ I-Outcome
, -X- _ I-Outcome
p -X- _ I-Outcome
= -X- _ I-Outcome
0.007 -X- _ I-Outcome
) -X- _ I-Outcome
and -X- _ I-Outcome
with -X- _ I-Outcome
a -X- _ I-Outcome
significantly -X- _ I-Outcome
lower -X- _ I-Outcome
mean -X- _ I-Outcome
viral -X- _ I-Outcome
load -X- _ I-Outcome
measured -X- _ I-Outcome
as -X- _ I-Outcome
log -X- _ I-Outcome
( -X- _ I-Outcome
10 -X- _ I-Outcome
) -X- _ I-Outcome
viral -X- _ I-Outcome
copies -X- _ I-Outcome
/ -X- _ I-Outcome
mL -X- _ I-Outcome
( -X- _ I-Outcome
mean -X- _ I-Outcome
difference -X- _ I-Outcome
: -X- _ I-Outcome
-0.89 -X- _ I-Outcome
, -X- _ I-Outcome
CI -X- _ I-Outcome
( -X- _ I-Outcome
95 -X- _ I-Outcome
: -X- _ I-Outcome
) -X- _ I-Outcome
-1.7 -X- _ I-Outcome
, -X- _ I-Outcome
-0.06 -X- _ I-Outcome
, -X- _ I-Outcome
p -X- _ I-Outcome
= -X- _ I-Outcome
0.04 -X- _ I-Outcome
) -X- _ I-Outcome
. -X- _ I-Outcome
Fewer -X- _ I-Outcome
students -X- _ I-Outcome
assigned -X- _ I-Outcome
to -X- _ I-Outcome
gargling -X- _ I-Outcome
experienced -X- _ I-Outcome
laboratory -X- _ I-Outcome
confirmed -X- _ I-Outcome
URTI -X- _ I-Outcome
, -X- _ I-Outcome
however -X- _ I-Outcome
this -X- _ I-Outcome
was -X- _ I-Outcome
not -X- _ I-Outcome
statistically -X- _ I-Outcome
significant -X- _ I-Outcome
( -X- _ I-Outcome
RR:0.82 -X- _ I-Outcome
, -X- _ I-Outcome
CI -X- _ I-Outcome
( -X- _ I-Outcome
95 -X- _ I-Outcome
) -X- _ I-Outcome
:0.53-1.26 -X- _ I-Outcome
, -X- _ I-Outcome
p -X- _ I-Outcome
= -X- _ I-Outcome
0.36 -X- _ I-Outcome
) -X- _ I-Outcome
. -X- _ O
CONCLUSIONS -X- _ O
: -X- _ O
These -X- _ O
results -X- _ O
suggest -X- _ O
that -X- _ O
vitamin -X- _ B-Outcome
D -X- _ I-Outcome
( -X- _ I-Outcome
3 -X- _ I-Outcome
) -X- _ I-Outcome
is -X- _ I-Outcome
a -X- _ I-Outcome
promising -X- _ I-Outcome
intervention -X- _ I-Outcome
for -X- _ I-Outcome
the -X- _ I-Outcome
prevention -X- _ I-Outcome
of -X- _ I-Outcome
URTI. -X- _ I-Outcome
Vitamin -X- _ I-Outcome
D -X- _ I-Outcome
( -X- _ I-Outcome
3 -X- _ I-Outcome
) -X- _ I-Outcome
significantly -X- _ I-Outcome
reduced -X- _ I-Outcome
the -X- _ I-Outcome
risk -X- _ I-Outcome
of -X- _ I-Outcome
laboratory -X- _ I-Outcome
confirmed -X- _ I-Outcome
URTI -X- _ I-Outcome
and -X- _ I-Outcome
may -X- _ I-Outcome
reduce -X- _ I-Outcome
the -X- _ I-Outcome
risk -X- _ I-Outcome
of -X- _ I-Outcome
clinical -X- _ I-Outcome
infections. -X- _ I-Outcome
TRIAL -X- _ O
REGISTRATION -X- _ O
: -X- _ O
Clinical -X- _ O
Trials -X- _ O
Registration -X- _ O
: -X- _ O
NCT01158560 -X- _ O
. -X- _ O

